Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

This single-group Phase I study evaluates the safety and feasibility of two oral psilocybin sessions given approximately 4 weeks apart, each delivered with trained facilitators and an overnight clinical observation period.

Participants receive preparatory psychological support (≥6 hours), an 8-hour dosing observation and overnight stay, and integration sessions; follow-up continues to approximately 26 weeks to assess safety and feasibility.